Funding co-led by Amplitude Ventures and an undisclosed major strategic investor to advance the ReSolv™ stent into additional human clinical trials
CALGARY, Alberta--(BUSINESS WIRE)--#aneurysm--Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an oversubscribed $27 million USD Series A equity financing. The round is co-led by Amplitude Ventures and an undisclosed major strategic partner. New participants in the investment syndicate include IAG Capital Partners and LifeArc Ventures, as well as returning investors, ShangBay Capital and METIS Innovative.
The ReSolv™ stent was developed by John Wong, M.D., co-founder and chief executive officer of Fluid Biomed, and Alim Mitha, M.D., co-founder, president and chief technology officer. Both are leading academic neurosurgeons at the University of Calgary.
Fluid Biomed’s unique bioabsorbable polymer-based stent technology has been validated by years of scientific research with functional benefits demonstrated in a first-in-human clinical study to treat brain aneurysms, a leading cause of stroke and disability. About 6.7 million people in the U.S. have unruptured brain aneurysms and more than 30,000 rupture and bleed each year, often leading to disability and death. Fluid Biomed plans to use the proceeds to further validate the ReSolv™ stent and its proprietary delivery system in expanded patient studies.
“Our exclusive technology has attracted the attention of international investors of the highest caliber with the depth and breadth of expertise to accelerate company evolution and make its medical devices available sooner to physicians and patients,” said Dr. Wong. Dr. Mitha added, “This additional strategic and financial capital will enable larger clinical trials as well as broaden our product pipeline. Empowered with greater resources, Fluid Biomed is well positioned to create the next generation of stents to heal those afflicted with brain aneurysms around the world.”
Jean-Francois Pariseau, co-founder and partner at Amplitude Ventures, said, “This financing will propel Fluid Biomed toward realization of the remarkable potential of the ReSolv™ stent. We are strong supporters of entrepreneurial scientists. Fluid Biomed’s founders have utilized their decades of experience to create a truly novel technology that will positively impact patient outcomes.”
About Fluid Biomed
Fluid Biomed Inc. is a clinical stage medical device company based in Calgary, Alberta, Canada, that is developing the next generation of stents to treat vascular disease. Founded by accomplished neurosurgeons with expertise in scientific research and clinical care, the company has created ReSolv™, the world’s first bioabsorbable polymer-based neurovascular stent to cure brain aneurysms, which are a leading cause of stroke and disability worldwide. Find out more at fluidbiomed.com.
About Amplitude Ventures
Amplitude Ventures is a full-stack venture capital firm using a unique growth model to build breakout companies based on groundbreaking technology and with world-class management teams. With more than $500 million in assets under management, Amplitude applies its proven, evidence-based approach to investing in leading precision medicine companies. Visit amplitudevc.com to learn more.
Contacts
Media Contact
Jeffrey Krasner, Slowey McManus Communications
jkrasner@sloweymcmanus.com
+1-617-840-9806
